Form 13F security
RPRX · Royalty Pharma
Class SHS CLASS A
As filed on Form 13F — long US-listed positions only. No shorts, cash, bonds, or non-13F assets appear here.
Filed up to 45 days after quarter end; holdings may have changed since.
Tracked managers holding it
Share and principal positions
| Manager | Quarter | Value | % of portfolio | SH/PRN qty | Put/call |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO | 2026-06-30 | $562M | 0.5% | SH 10,015,578 | — |
| Patient Capital Management, LLC | 2026-06-30 | $202M | 6.6% | SH 3,598,808 | — |
| HORIZON KINETICS ASSET MANAGEMENT LLC | 2026-06-30 | $19M | 0.2% | SH 344,861 | — |
| Bridgewater Associates, LP | 2026-06-30 | $12M | <0.1% | SH 219,687 | — |
| Point72 Asset Management, L.P. | 2026-06-30 | $6.0M | <0.1% | SH 106,549 | — |
Total $801M across 5 of 69 managers.
Sums are across tracked reports, not unique economic ownership.
BAILLIE GIFFORD & CO — Combined report.
Filed rows (8) — as filed
The filer reports some securities in multiple rows; rows are shown as filed.
| Manager | Class | Put/call | Value | % of portfolio | SH/PRN qty | Source |
|---|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO | SHS CLASS A | — | $298M | 0.3% | SH 5,319,224 | 0001088875-26-000057 |
| Patient Capital Management, LLC | SHS CLASS A | — | $202M | 6.6% | SH 3,598,808 | 0001854794-26-000005 |
| BAILLIE GIFFORD & CO | SHS CLASS A | — | $169M | 0.2% | SH 3,016,738 | 0001088875-26-000057 |
| BAILLIE GIFFORD & CO | SHS CLASS A | — | $59M | <0.1% | SH 1,057,064 | 0001088875-26-000057 |
| BAILLIE GIFFORD & CO | SHS CLASS A | — | $35M | <0.1% | SH 622,552 | 0001088875-26-000057 |
| HORIZON KINETICS ASSET MANAGEMENT LLC | SHS CLASS A | — | $19M | 0.2% | SH 344,861 | 0001398344-26-014047 |
| Bridgewater Associates, LP | SHS CLASS A | — | $12M | <0.1% | SH 219,687 | 0001350694-26-000003 |
| Point72 Asset Management, L.P. | SHS CLASS A | — | $6.0M | <0.1% | SH 106,549 | 0000919574-26-005520 |
Quarter-to-quarter notes
Reported change, not a confirmed trade: this compares quarter-end reports filed up to 45 days later, and the position may since have changed. Amendments, corporate actions, and changes in reporting scope can also move these rows. Value change compares period-end reported values; for continuing rows it includes market price movement.
Newly reported by Bridgewater Associates, LP.
Changes appear only where the prior quarter's validated report exists.